Global Liver Institute

Web Releases

GLOBAL LIVER INSTITUTE

Web Releases
Global Communities Rally around Third Deadliest Cancer – Liver Cancer

Global Communities Rally around Third Deadliest Cancer – Liver Cancer

(Washington, D.C., October 1, 2023) – Today marks the start of Liver Cancer Awareness Month, which will feature the monthlong #OctoberIs4Livers multifaceted campaign led by Global Liver Institute (GLI) to promote awareness of the disease, mark progress made, and identify key areas of global focus to make improvements for liver cancer patients. In addition to a comprehensive social media campaign, “Liver Cancer Lessons” education series, and featured conversations with expert guests and GLI CEO Donna R. Cryer, JD, partners around the world will host Open House events to inform and advocate to fight liver disease in their communities.

read more
GLI Supports NIH Naming Dr. Marrazzo as New Director of the National Institute of Allergy and Infectious Diseases

GLI Supports NIH Naming Dr. Marrazzo as New Director of the National Institute of Allergy and Infectious Diseases

Global Liver Institute supports the selection of Jeanne M. Marrazzo, M.D., as director of the National Institute of Allergy and Infectious Diseases (NIAID) by the acting director of the NIH. Dr. Marrazzo is currently the director of the Division of Infectious Diseases at the University of Alabama at Birmingham and is a Fellow of the American College of Physicians and of the Infectious Diseases Society of America.

read more
GLI Urges Passage of the Treat and Reduce Obesity Act (TROA)

GLI Urges Passage of the Treat and Reduce Obesity Act (TROA)

Global Liver Institute recognizes the relationship between nonalcoholic fatty liver disease (NAFLD), its advanced form, nonalcoholic steatohepatitis (NASH), and obesity. Preventing liver disease is directly associated with treating and reducing obesity. Worldwide, NASH affects more than 148 million people and continues to become more prevalent each year.

read more
ICER Midwest CEPAC Works to Keep Up with Well-Informed NASH Patient Advocates

ICER Midwest CEPAC Works to Keep Up with Well-Informed NASH Patient Advocates

On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic Acid (OCA) for Non-Alcoholic Steatohepatitis: Effectiveness and Value. While the evidence presented for both drugs was deemed effective in fibrosis regression, ICER inconsistently voted to show that there was only a net health benefit in favor of resmetirom, being superior to lifestyle management alone, and not in OCA.

read more